Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in man study of SGT 212 in Friedreich's-ataxia patients.

Next Previous
X
Search
Trial Profile

A First in man study of SGT 212 in Friedreich's-ataxia patients.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGT 212 (Primary) ; SGT 212 (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 21 Jan 2025 According to Solid Biosciences Media releases, dosing is expected to initiate in the second half of 2025 and participants in the trial will be followed for five years after receiving SGT-212.
    • 14 Jan 2025 New trial record
    • 07 Jan 2025 According to Solid Biosciences Media releases, company announces expects to initiate a first-in-human Phase 1b clinical trial In the second half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top